PLANEGG / MUNIQUE (dpa-AFX) – The biotechnology company Morphosys receives a payment of $ 3 million from China. Background is the start of a Phase 3 study with MOR202 / TJ202 in multiple myeloma, the company said on Monday evening. If successful, this could lead to a request for approval for the region of China. Morphosys works closely with Chinese industry colleague I-Mab Pharma./he
AXC0283 2019-04-29 / 23: 02
Copyright dpa-AFX Business News GmbH. All rights reserved. Redistribution, republishing or permanent storage without the prior express consent of dpa-AFX is not permitted.